Organon & Co (OGN) - Bathi pungkasan

OGN (organon.com) - tandha merek perusahaan

Stable income from biosimilars and women's health is currently creating a tangible effect, while 0.21 determines the current magnitude of the indicator. The final financial result of Organon & Co. (OGN) demonstrates the actual efficiency of the business on a daily basis. Organon & Co. (OGN) strives for global leadership in reproductive medicine through the acquisition of biotech firms, relying on the monetization of its specialized portfolio and the launch of affordable generics for complex drugs.

Organon (OGN): Bathi resik perusahaan saka 04.07.2022 nganti 30.10.2026

Rincian metrik keuangan lan pasar Organon (OGN)

- nilai pasar lan prakiraan target analis:
Rega saham Organon Pharma|OGN - Target konsensus
- indikator kapitalisasi pasar:
Nilai pasar Organon Pharma|OGN - Rega Nyata Tumbas Perusahaan Kanthi Wutuh
- rincian valuasi buku bisnis:
Nilai Akuntansi saben Saham Organon|OGN - Nilai Buku Perusahaan|Koefisien Nilai Pasar marang Nilai Buku organon.com|OGN - Aset Agregat Perusahaan
- informasi babagan utang lan solvabilitas:
Rasio Total Utang marang Ekuitas Organon & Co.|OGN - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal Organon & Co|OGN - Utang perusahaan|Rasio utang marang nilai buku Organon Pharma|OGN - Utang jangka dawa perusahaan|Utang jangka cendhak Organon|Rasio jangkoan perantara organon.com
- data bathi resik lan rasio valuasi:
OGN - Bathi resik
Analisis dhasar perusahaan:Organon Pharma
Barang utama Organon & Co.

Stable demand for women's health products provides Organon & Co. (OGN) with a predictable cash flow to reduce debt obligations. The company's net profit dynamics aggregate daily financial results into a single trend, allowing investors to assess capital management efficiency and the real impact of corporate events on the asset's fundamental value through the analysis of this chart.

Pesaing utama

Daré Bioscience, Inc. (DARE) - Bathi resik|Penghasilan resik TXMD|PTN: Bathi pungkasan